Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients
The American Surgeon™ · 2024
DOI: 10.1177/00031348241241696 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Surgeon™, 2024. Verfasst von Ryan Taylor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, University of Tennessee Medical Center, Knoxville, TN, USA. Hauptthemen laut MEDLINE: Enoxaparin, Anticoagulants, Fibrinolytic Agents, Bariatric Surgery. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.
- Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.
ORCID-Profile: Kyle Kleppe, John Yates
Zitieren
APA
Taylor, R., Madion, M., Kleppe, K., Mancini, M., Mancini, G., Hutson, M., Yates, J., & Daigle, H. (2024). Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients. The American Surgeon™. https://doi.org/10.1177/00031348241241696
Vancouver
Taylor R, Madion M, Kleppe K, Mancini M, Mancini G, Hutson M, et al. Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients. The American Surgeon™. 2024. doi:10.1177/00031348241241696
BibTeX
@article{Taylor2024,
author = {Taylor, Ryan and Madion, Matthew and Kleppe, Kyle and Mancini, Matthew and Mancini, Gregory and Hutson, Mitchell and Yates, John and Daigle, Haley},
title = {Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients},
journal = {The American Surgeon™},
year = {2024},
doi = {10.1177/00031348241241696}
}
EUVIMED